To evaluate whether inhibition of LSD1 by ZY0511 suppresses HCC growth in vivo, two cell‐derived xenograft (CDX) models (HepG2 and Hep3B) and two patient‐derived xenograft (PDX) models were established, and ZY0511 was intraperitoneally (i.p.)administered once tumor volume reached approximately 100 mm3. This evidence concerns the gene KDM1A and neoplasm.